Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in <i>De Novo</i> Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study
This study identified a novel noninvasive blood-based biomarker model (b.TRPC) using ctDNA to predict PFS in mHSPC. Analyzing TP53, RB1, PTEN, and CDK12 alterations, it outperformed traditional ctDNA% markers. Findings highlight ctDNA-based biomarkers' potential to guide personalized treatment, bridging real-world and trial data to aid mHSPC management.
Authors
- Ruiliang Wang (ORCID: https://orcid.org/0000-0001-5508-2785)
- Chenyi Zhu (ORCID: https://orcid.org/0009-0004-5334-7996)
- Bin Yang (ORCID: https://orcid.org/0000-0002-3944-8035)
- Wentao Luo (ORCID: https://orcid.org/0009-0002-8549-2480)
- Wujianhong Liu (ORCID: https://orcid.org/0000-0001-8208-4348)
- Chengqi Jin (ORCID: https://orcid.org/0009-0009-7684-772X)
- Tingting Zhao (ORCID: https://orcid.org/0009-0009-3003-2779)
- Changcheng Guo (ORCID: https://orcid.org/0000-0001-9145-2384)
- Wei Chen (ORCID: https://orcid.org/0000-0002-2139-1368)
- Jing Xu (ORCID: https://orcid.org/0009-0008-0689-7783)
Institutions
- Tongji University (CN)
- Sun Yat-sen University (CN)
- Fudan University (CN)
- Zhongshan Hospital (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- Shanghai Tenth People's Hospital (CN)
- Hongzhiwei Technology (China) (CN)
- Shanghai Clinical Research Center (CN)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2025-11-11
- DOI
- https://doi.org/10.1158/2767-9764.crc-25-0384
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Shanghai Municipal Health Commission
- National Natural Science Foundation of China
- Fudan University
- National Health Commission of the People's Republic of China
- Wu Jieping Medical Foundation